A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters

Journal of Neuroscience

Volumn 23, Issue 11, 2003, Pages 4470-4478

  Hahn, Maureen K ^a   Robertson, David ^a   Blakely, Randy D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Norepinephrine; Orthostatic intolerance; SLC6A2; Trafficking; Transporter

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; IODINE 125; NORADRENALIN; NORADRENALIN TRANSPORTER; RADIOLIGAND; TRITIUM;

ALLELE; ANIMAL CELL; ARTICLE; AUTONOMIC DYSFUNCTION; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; BRAIN; CELL STRAIN COS7; GENE; GENE EXPRESSION; GENE MUTATION; GLYCOSYLATION; HEART RATE; IMMUNOPRECIPITATION; ISOTOPE LABELING; MEMBRANE BINDING; NEUROTRANSMISSION; NONHUMAN; ORTHOSTATIC DYSREGULATION; PLASMID; PRIORITY JOURNAL; SLC6A2 GENE;

EID: 0038118243     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-11-04470.2003     Document Type: Article

References (64)

1. Adkins EM, Barker EL, Blakely RD (2001) Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 59:514-523.
2. Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD (1998a) Acute regulation of norepinephrine transport. I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 287:733-743.
3. Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD (1998b) Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther 287:744-751.
4. Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kubler W, Haass M (2001) The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 33:461-472.
5. Barker EL, Moore KR, Rakhshan F, Blakely RD (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705-4717.
6. Bauman PA, Blakely RD (2002) Determinants within the C-terminus of the human norepinephrine transporter dictate transporter trafficking, stability, and activity. Arch Biochem Biophys 404:80-91.
7. Blakely RD (2001) Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 21:8319-8323.
8. Bohm M, La Rosee K, Schwinger RH, Erdmann E (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25:146-153.
9. Bohm M, Castellano M, Flesch M, Maack C, Moll M, Paul M, Schiffer F, Zolk O (1998) Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy. Hypertension 32:831-837.
10. Brüss M, Kunz J, Lingen B, Bönisch H (1993) Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet 91:278-280.
11. Buck KJ, Amara SG (1995) Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol 48:1030-1037.
12. Cao Y, Li M, Mager S, Lester HA (1998) Amino acid residues that control pH modulation of transport-associated current in mammalian serotonin transporters. J Neurosci 18:7739-7749.
13. Chang AS, Starnes DM, Chang SM (1998) Possible existence of quaternary structure in the high-affinity serotonin transport complex. Biochem Biophys Res Commun 249:416-421.
14. Chen JG, Sachpatzidis A, Rudnick G (1997) The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem 272:28321-28327.
15. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877-885.
16. Eskandari S, Kreman M, Kavanaugh MP, Wright EM, Zampighi GA (2000) Pentameric assembly of a neuronal glutamate transporter. Proc Natl Acad Sci USA 97:8641-8646.
17. Esler M, Jackman G, Bobik A, Leonard P, Kelleher D, Skews H, Jennings G, Korner P (1981) Norepinephrine kinetics in essential hypertension. Defective neuronal uptake of norepinephrine in some patients. Hypertension 3:149-156.
18. Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63:845-914.
19. Forlani G, Bossi E, Ghirardelli R, Giovannardi S, Binda F, Bonadiman L, Ielmini L, Peres A (2001) Mutation K448E in the external loop 5 of rat GABA transporter rGAT1 induces pH sensitivity and alters substrate interactions. J Physiol (Lond) 536:479-494.
20. Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (1995) Sodiumdependent norepinephrine-induced currents in norepinephrinetransporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 198:2197-2212.
21. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG (1994) Delineation ofdiscrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269:15985-15988.
22. Golovanevsky V, Kanner BI (1999) The reactivity of the gammaaminobutyric acid transporter GAT-1 toward sulfhydryl reagents is conformationally sensitive. Identification of a major target residue. J Biol Chem 274:23020-23026.
23. Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269:7124-7130.
24. Hahn MK, Blakely RD (2002a) Gene organization and polymorphisms of monoamine transporters. relationship to psychiatric and other complex diseases. In: Neurotransmitter transporters. Structure, function, and regulation (Reith MEA, ed), pp 111-169. Totowa, NJ: Humana.
25. Hahn MK, Blakely RD (2002b) Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J 2:217-235.
26. Hastrup H, Karlin A, Javitch JA (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci USA 98:10055-10060.
27. Iversen LL (1961) The uptake of noradrenaline by the isolated rat heart. Br J Pharmacol 21:523-537.
28. Jacob G, Shannon JR, Costa F, Furlan R, Biaggioni I, Mosqueda-Garcia R, Robertson RM, Robertson D (1999) Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Circulation 99:1706-1712.
29. Jayanthi LD, Prasad PD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathyv (1993) Sodium- and chloride-dependent, cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. Biochemistry 32:12178-12185.
30. Kilic F, Rudnick G (2000) Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci USA 2000 97:3106-3111.
31. Kitayama S, Ikeda T, Mitsuhata C, Sato T, Morita K, Dohi T (1999) Dominant negative isoform of rat norepinephrine transporter produced by alternative RNA splicing. J Biol Chem 274:10731-10736.
32. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
33. Leonard BE (1997) The role of noradrenaline in depression: a review. J Psychopharmacol 11:S39-S47.
34. Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14:4903-4914.
35. Margeta-Mitrovic M, Jan YN, Jan LY (2000) A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 27:97-106.
36. Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD (1994) Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. J Biol Chem 269:12290-12297.
37. Melikian HE, Ramamoorthy S, Tate CG, Blakely RD (1996) Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol Pharmacol 50:266-276.
38. Merlet P, Dubois-Rande JL, Adnot S, Bourguignon MH, Benvenuti C, Loisance D, Valette H, Castaigne A, Syrota A (1992) Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 19:10-16.
39. Mitchell K, Oke AF, Adams RN (1994) In vivo dynamics of norepinephrine release-reuptake in multiple terminal field regions of rat brain. J Neurochem 63:917-926.
40. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, Bouvier M (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-895.
41. - neurotransmitter transporters. J Neurochem 71:1785-1803.
42. Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354.
43. Paczkowski FA, Bonisch H, Bryan-Lluka LJ (2002) Pharmacological properties of the naturally occurring Ala457 Pro variant of the human norepinephrine transporter. Pharmacogenetics 12:165-173.
44. Ramsey IS, DeFelice LJ (2002) Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor. J Biol Chem 277:14475-14482.
45. Ritz MC, Cone EJ, Kuhar MJ (1990) Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structureactivity study. Life Sci 46:635-645.
46. Sacchetti G, Bernini M, Bianchetti A, Parini S, Invernizzi RW, Samanin R (1999) Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol 128:1332-1338.
47. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522.
48. Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH (2001) Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 276:3805-3810.
49. Schnell O, Muhr D, Weiss M, Dresel S, Haslbeck M, Standl E (1996) Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 45:801-805.
50. Scholze P, Freissmuth M, Sitte HH (2002) Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1. J Biol Chem 277:43682-43690.
51. Schomig A, Dart AM, Dietz R, Mayer E, Kubler W (1984) Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res 55:689-701.
52. Schomig E, Fischer P, Schonfeld CL, Trendelenburg U (1989) The extent of neuronal re-uptake of 3H-noradrenaline in isolated vasa deferentia and atria of the rat. Naunyn Schmiedebergs Arch Pharmacol 340:502-508.
53. Schomig A, Haass M, Richardt G (1991) Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 12:38-47.
54. Schroeter S, Levey AI, Blakely RD (1997) Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol Cell Neurosci 9:170-184.
55. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (2000) Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J Comp Neurol 420:211-232.
56. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (2000) Clues to the origin of orthostatic intolerance: a genetic defect in the cocaine- and antidepressant-sensitive norepinephrine transporter. New Eng J Med 342:541-549.
57. Smicun Y, Campbell SD, Chen MA, Gu H, Rudnick G (1999) The role of external loop regions in serotonin transport. loop scanning mutagenesis of the serotonin transporter external domain. J Biol Chem 274:36058-36064.
58. Sung U, Apparsundaram S, Galli A, Kahlig K, Savchenko V, Schroeter S, Quick MW, Blakely RD (2003) A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 23:1697-1709.
59. Tatsumi M, Groshan K, Blakely PO, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258.
60. 3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427-436.
61. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG (2002) Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol. Chem 278:2731-2739.
62. Wilkerson RD, Sanders PW (1978) The antiarrhythmic action of amitriptyline on arrhythmias associated with myocardial infarction in dogs. Eur J Pharmacol 51:193-198.
63. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465-471.
64. Zhou Z, Gong Q, January CT (1999) Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. pharmacological and temperature effects. J Biol Chem 274:31123-31126.